B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund Has $3.98 Million Stake in Amgen Inc. (AMGN)

B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,240 shares of the medical research company’s stock after purchasing an additional 1,532 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Amgen were worth $3,977,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TrimTabs Asset Management LLC raised its stake in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares during the period. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after purchasing an additional 4 shares during the period. Nelson Roberts Investment Advisors LLC purchased a new stake in shares of Amgen during the first quarter valued at approximately $121,000. Finally, Signature Estate & Investment Advisors LLC raised its stake in shares of Amgen by 13.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 95 shares during the period. Institutional investors own 78.14% of the company’s stock.

A number of research firms have recently issued reports on AMGN. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research note on Thursday, September 7th. Cann reiterated a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Mizuho reiterated a “buy” rating and set a $183.00 price objective (down previously from $195.00) on shares of Amgen in a research note on Monday, August 21st. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Argus lifted their price target on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $186.04.

ILLEGAL ACTIVITY NOTICE: “B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund Has $3.98 Million Stake in Amgen Inc. (AMGN)” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.themarketsdaily.com/2017/09/12/b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund-has-3-98-million-stake-in-amgen-inc-amgn.html.

Shares of Amgen Inc. (AMGN) traded up 0.8237% during trading on Tuesday, hitting $188.0261. 1,341,401 shares of the stock traded hands. The firm’s 50-day moving average price is $173.58 and its 200-day moving average price is $168.69. The company has a market cap of $137.20 billion, a price-to-earnings ratio of 17.1260 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $188.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the company posted $2.84 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.47%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply